Spark Therapeutics Inc. (ONCE) Trading Up 2.5%
Spark Therapeutics Inc. (NASDAQ:ONCE) was up 2.5% on Thursday . The company traded as high as $54.49 and last traded at $53.24, with a volume of 257,140 shares trading hands. The stock had previously closed at $51.95.
A number of equities research analysts have weighed in on ONCE shares. Zacks Investment Research upgraded Spark Therapeutics from a “hold” rating to a “buy” rating and set a $39.00 price objective for the company in a research note on Thursday, April 14th. Evercore ISI started coverage on Spark Therapeutics in a report on Tuesday, April 12th. They issued a “buy” rating and a $37.00 target price on the stock. SunTrust Banks Inc. started coverage on Spark Therapeutics in a report on Monday, March 21st. They issued a “buy” rating and a $64.00 target price on the stock. Cowen and Company reissued a “buy” rating and issued a $75.00 target price on shares of Spark Therapeutics in a report on Wednesday, May 4th. Finally, Cantor Fitzgerald started coverage on Spark Therapeutics in a report on Thursday, June 2nd. They issued a “buy” rating and a $100.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $58.56.
The firm has a 50-day moving average price of $51.44 and a 200 day moving average price of $38.25. The firm’s market cap is $1.52 billion.
Spark Therapeutics (NASDAQ:ONCE) last released its earnings results on Wednesday, May 4th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by $0.11. The business earned $1.29 million during the quarter, compared to the consensus estimate of $1.48 million. The business’s quarterly revenue was down 43.2% on a year-over-year basis. On average, equities research analysts expect that Spark Therapeutics Inc. will post ($3.92) EPS for the current fiscal year.
In other Spark Therapeutics news, Director Anand Mehra sold 500 shares of the stock in a transaction that occurred on Tuesday, May 31st. The stock was sold at an average price of $60.00, for a total transaction of $30,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Katherine A. High sold 10,000 shares of the stock in a transaction that occurred on Monday, May 23rd. The stock was sold at an average price of $54.42, for a total value of $544,200.00. Following the transaction, the insider now directly owns 270,100 shares in the company, valued at approximately $14,698,842. The disclosure for this sale can be found here.
A number of hedge funds and institutional investors have recently added to or reduced their stakes in the company. Casdin Capital LLC purchased a new position in Spark Therapeutics during the fourth quarter worth approximately $6,570,000. TD Asset Management Inc. increased its position in Spark Therapeutics by 72.2% in the fourth quarter. TD Asset Management Inc. now owns 58,187 shares of the company’s stock worth $2,636,000 after buying an additional 24,400 shares in the last quarter. UBS Oconnor LLC purchased a new position in Spark Therapeutics during the fourth quarter worth approximately $4,395,000. Finally, CAM Group Holding A S increased its position in Spark Therapeutics by 1.8% in the fourth quarter. CAM Group Holding A S now owns 78,620 shares of the company’s stock worth $3,562,000 after buying an additional 1,400 shares in the last quarter.
Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. Spark’s product candidate, SPK-RPE65, which is in Phase III clinical trial stage, targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs), caused by non-sex linked or autosomal recessive mutations in the RPE65 gene.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.